Coherus Oncology (FRA:8C5) Long-Term Debt: €32.13 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8C5 Coherus Oncology Inc FRA:8C5
49 GF Score
Price €1.18
GF Value €0.64
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology Long-Term Debt?

Coherus Oncology FRA:8C5 -4.85% 49 Long-Term Debt is €32.13 Mil as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 49/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Coherus Oncology's Long-Term Debt for the quarter that ended in Mar. 2026 was €32.13 Mil.

Coherus Oncology's quarterly Long-Term Debt increased from Sep. 2025 (€31.49 Mil) to Dec. 2025 (€31.64 Mil) and increased from Dec. 2025 (€31.64 Mil) to Mar. 2026 (€32.13 Mil).

Coherus Oncology's annual Long-Term Debt declined from Dec. 2023 (€434.08 Mil) to Dec. 2024 (€253.01 Mil) and declined from Dec. 2024 (€253.01 Mil) to Dec. 2025 (€31.64 Mil).

Coherus Oncology  (FRA:8C5) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Coherus Oncology Long-Term Debt Related Terms

Coherus Oncology Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology Long-Term Debt Chart

Coherus Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 361.33 444.68 434.08 253.01 31.64

Coherus Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 245.45 31.96 31.49 31.64 32.13
FRA:8C5
49GF Score
Coherus Oncology Inc FRA:8C5
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €32.13 Mil mean?
Coherus Oncology (FRA:8C5) has a Long-Term Debt of €32.13 Mil as of Mar. 2026.
Is Coherus Oncology's Long-Term Debt too high?
Coherus Oncology's current Long-Term Debt is €32.13 Mil. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Long-Term Debt compare to TARA and KPTI?
Coherus Oncology's Long-Term Debt of €32.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Coherus Oncology's current Long-Term Debt is €32.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €1.18 — trading 84.1% above its estimated fair value. The current Long-Term Debt is €32.13 Mil. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Long-Term Debt is €32.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.18 is trading 84.1% above its estimated GF Value™ of €0.64. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

  • Long-Term Debt: €32.13 Mil
  • GF Value™: €0.64 vs. price of €1.18 (84.1% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score

Get the complete analysis for FRA:8C5

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€0.64
GF Value